JP2009504774A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009504774A5 JP2009504774A5 JP2008527161A JP2008527161A JP2009504774A5 JP 2009504774 A5 JP2009504774 A5 JP 2009504774A5 JP 2008527161 A JP2008527161 A JP 2008527161A JP 2008527161 A JP2008527161 A JP 2008527161A JP 2009504774 A5 JP2009504774 A5 JP 2009504774A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- administered
- use according
- saha
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 16
- 229960000237 vorinostat Drugs 0.000 claims 16
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims 11
- 229940099419 targretin Drugs 0.000 claims 7
- 238000011260 co-administration Methods 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 4
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 4
- 150000004492 retinoid derivatives Chemical class 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 claims 2
- 239000003524 antilipemic agent Substances 0.000 claims 2
- 229940034208 thyroxine Drugs 0.000 claims 2
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims 1
- 229960002297 fenofibrate Drugs 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70959905P | 2005-08-18 | 2005-08-18 | |
| US73375205P | 2005-11-04 | 2005-11-04 | |
| PCT/US2006/032282 WO2007022408A2 (en) | 2005-08-18 | 2006-08-18 | Combination methods of saha and targretin for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009504774A JP2009504774A (ja) | 2009-02-05 |
| JP2009504774A5 true JP2009504774A5 (enExample) | 2009-09-10 |
Family
ID=37758430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008527161A Withdrawn JP2009504774A (ja) | 2005-08-18 | 2006-08-18 | 癌を治療するためにｓａｈａ及びターグレチンの併用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090227674A1 (enExample) |
| EP (1) | EP1933825A2 (enExample) |
| JP (1) | JP2009504774A (enExample) |
| AU (1) | AU2006279400A1 (enExample) |
| CA (1) | CA2617623A1 (enExample) |
| WO (1) | WO2007022408A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ550185A (en) | 2002-03-04 | 2008-10-31 | Merck Hdac Res Llc | Methods of inducing terminal differentiation Methods of inducing terminal differentiation |
| TWI415603B (zh) | 2005-05-20 | 2013-11-21 | Merck Sharp & Dohme | １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法 |
| JP2009510114A (ja) | 2005-09-30 | 2009-03-12 | ビテ ファーマシューティカルズ， インコーポレイテッド | 特定のｒｘｒアゴニストによる癌治療 |
| WO2008132443A1 (en) | 2007-04-25 | 2008-11-06 | Cyclacel Limited | Use of sapacitabine to treat proliferative disease |
| US10653650B2 (en) | 2011-12-13 | 2020-05-19 | Io Therapeutics, Inc. | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists |
| US20130190395A1 (en) | 2011-12-13 | 2013-07-25 | Dartmouth College | Autoimmune disorder treatment using rxr agonists |
| ES2806258T3 (es) * | 2013-12-03 | 2021-02-17 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona desacetilasa y fármacos inmunomoduladores |
| MX2016015092A (es) * | 2014-05-21 | 2017-05-09 | Nat Inst Advanced Ind Science & Tech | Inhibidor de proliferacion de celulas madre cancerosas. |
| US10799479B2 (en) * | 2015-04-10 | 2020-10-13 | Bioresponse, L.L.C. | Self-emulsifying formulations of DIM-related indoles |
| PL3368080T3 (pl) | 2015-10-31 | 2023-09-11 | Io Therapeutics, Inc. | Leczenie zaburzeń układu nerwowego z zastosowaniem kombinacji agonistów rxr i hormonów tarczycy |
| SG11201807250PA (en) * | 2016-03-10 | 2018-09-27 | Io Therapeutics Inc | Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones |
| CN115227826A (zh) * | 2016-03-10 | 2022-10-25 | Io治疗公司 | Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途 |
| WO2018089861A1 (en) * | 2016-11-11 | 2018-05-17 | The Regents Of The University Of California | Methods and compositions for the treatment of cancer and metabolic diseases |
| AU2018335393A1 (en) | 2017-09-20 | 2020-04-02 | Io Therapeutics, Inc. | Treatment of disease with esters of selective RXR agonists |
| WO2020232399A1 (en) * | 2019-05-16 | 2020-11-19 | The Regents Of The University Of California | Compositions comprising hdac inhibitors and retinoids |
| US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
| JP2024543621A (ja) | 2021-12-07 | 2024-11-21 | アイオー セラピューティクス インコーポレイテッド | Ｈｅｒ２＋がんの治療におけるｒｘｒアゴニストおよびタキサンの使用 |
| JP2024544223A (ja) | 2021-12-07 | 2024-11-28 | アイオー セラピューティクス インコーポレイテッド | Ｈｅｒ２＋がんの治療におけるｒｘｒアゴニストの使用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002060430A1 (en) * | 2001-02-01 | 2002-08-08 | Cornell Research Foundation, Inc. | Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors |
-
2006
- 2006-08-18 US US11/990,724 patent/US20090227674A1/en not_active Abandoned
- 2006-08-18 JP JP2008527161A patent/JP2009504774A/ja not_active Withdrawn
- 2006-08-18 AU AU2006279400A patent/AU2006279400A1/en not_active Abandoned
- 2006-08-18 EP EP06813528A patent/EP1933825A2/en not_active Withdrawn
- 2006-08-18 CA CA002617623A patent/CA2617623A1/en not_active Abandoned
- 2006-08-18 WO PCT/US2006/032282 patent/WO2007022408A2/en not_active Ceased